Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00589420
- Testing
- docetaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer.
- Trial name
- NCT00002924
- Testing
- mutation analysis
- Where
- 49 sites in United States
- Volunteers
- 184 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer, Prostate Adenocarcinoma
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Disease
- Trial name
- NCT03503643
- Testing
- Hemigland Cryoablation
- Where
- United States
- Volunteers
- 354 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00031889
- Testing
- Exemestane, Exemestane+bicalutamide
- Where
- 12 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01200810
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.
- Trial name
- NCT02135484
- Testing
- Alpharadin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
Prostate Adenocarcinoma
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease.
- Trial name
- NCT06022822
- Testing
- Biopsy Procedure, Biospecimen Collection, Urolithin A Supplement
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002602
- Testing
- 3D-CRT
- Where
- 228 sites in United States, Canada
- Volunteers
- 1,084 people
- Sponsor
- Radiation Therapy Oncology Group
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03649841
- Testing
- Antiandrogen Therapy, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Medullary Thyroid Cancer, Medullary Thyroid Carcinoma
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
Rationale: In patients with medullary thyroid cancer (MTC), molecular imaging is used to assess the extent of disease in the primary diagnostic process and follow-up period to determine possible therapeutic options.
- Conditions
- Medullary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Cancer, Medullary
- Trial name
- MIMETIC (NCT05534594)
- Testing
- 18F-PSMA-1007
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- University Medical Center Groningen
Urological Malignancies, Prostate Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles.
- Conditions
- Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer
- Trial name
- NCT04625556
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Hormone Refractory Prostate Cancer
Radiotherapy vs Observation for CRPC
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
- Trial name
- NCT01590498
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhengzhou University
Prostate Cancer
Fulvestrant in Treating Patients With Advanced Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00244998
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.
- Trial name
- NCT00005947
- Testing
- sipuleucel-T
- Where
- 34 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dendreon
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- AtezoCab (NCT05168618)
- Testing
- Atezolizumab, Cabozantinib S-malate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.